Full-Time

Director / Senior Director

CMC Drug Substance

Superluminal Medicines

Superluminal Medicines

51-200 employees

ML-driven design of candidate small molecules

No salary listed

Boston, MA, USA

Remote

The role is virtual, with domestic and international travel as needed.

Master's, PhD

Category
Biology & Biotech (1)

Get referred to Superluminal Medicines

See people who can refer or advise you

Requirements
  • A Master of Science degree with at least 15 years of experience or a Doctor of Philosophy degree with at least 10 years of experience in Organic Chemistry or a related field.
  • Expertise in small molecule synthesis, process development, and analytical method development for intermediates, drug substances, and structural alert impurities.
  • Proven experience in impurity management, solid-state development and characterization, and Good Manufacturing Practice manufacturing.
  • Demonstrated success in technology transfer and contract development and manufacturing organization management.
  • Experience authoring regulatory documents, including Investigational New Drug applications, Investigational Medicinal Product Dossiers, amendments, and annual reports.
  • Experience managing Good Manufacturing Practice clinical supply, labeling, storage, and shipment.
  • Willingness to travel domestically and internationally as needed.
Responsibilities
  • Lead early-stage Chemistry, Manufacturing, and Controls drug substance development in a virtual environment.
  • Propose alternative synthetic routes that optimize yield, purity, and scalability.
  • Manage contract development and manufacturing organizations to execute route scouting and scale-up to small demonstration batches.
  • Develop scalable, robust processes and purification strategies, including purging critical reagents and byproducts.
  • Design processes capable of delivering large initial toxicology batches, especially when high No Observed Adverse Effect Level demands require atypically large quantities.
  • Support aggressive timelines where 13-week toxicology studies may run in parallel with Phase 1 by establishing an early solid, scalable process.
  • Lead solid-state development to enhance solubility, stability, and pharmacokinetic performance through salt or co-crystal formation.
  • Develop crystallization processes, determine metastable zones, and establish control strategies for the desired solid form.
  • Ensure timely delivery of materials with the required quantity and purity under aggressive timelines.
  • Lead development and execution of impurity-enriched 28-day toxicology batches, including scale-up and impurity spiking.
  • Support subsequent campaigns at increasing scale to meet Phase 1, Phase 2, and extended toxicology requirements.
  • Develop and implement phase-appropriate strategies to identify, control, and purge toxic reagents, byproducts, and mutagenic impurities.
  • Ensure adherence to current Good Manufacturing Practice standards and internal quality expectations.
  • Review and approve manufacturing documentation, including batch records and deviation reports.
  • Support audits, investigations, and continuous improvement initiatives.
  • Author and review Chemistry, Manufacturing, and Controls sections of regulatory filings, including Investigational New Drug applications, Investigational Medicinal Product Dossiers, briefing packages, annual reports, and amendments.
  • Contribute to regulatory strategy and responses to health authority inquiries.
  • Maintain comprehensive documentation to support product lifecycle management.
  • Collaborate with Drug Product, Analytical, Quality, Regulatory, Toxicology, and Clinical Supply teams.
  • Provide scientific and operational input to project teams.
  • Contribute to intellectual property strategy and cross-functional Chemistry, Manufacturing, and Controls initiatives.
  • Develop and manage realistic timelines for research and development, manufacturing campaigns, and Investigational New Drug preparation aligned with clinical and toxicology milestones.
  • Lead contract development and manufacturing organizations proactively by providing clear guidance, actionable solutions, and rapid problem-solving.
  • Understand the business value of Chemistry, Manufacturing, and Controls development and its impact on program strategy.
  • Apply Design of Experiments and Quality by Design principles for late-stage development post-2029.
Desired Qualifications
  • Experience managing toxic and mutagenic impurities and preparing regulatory documentation is highly preferred.
  • Hands-on experience in salt, co-crystal, and polymorph screening; stability and solubility evaluation; and pharmacokinetic comparison.
  • Strong leadership, collaboration, and communication skills, with the ability to influence across disciplines.
  • Excellent interpersonal, technical writing, presentation, and oral communication skills.
  • Strong business awareness and ability to prioritize in a fast-moving, lean organization.
  • Expected to operate with high ownership and accountability for delivery, timelines, and decision-making in a lean, fast-paced organization.
Superluminal Medicines

Superluminal Medicines

View

Superluminal Medicines develops small-molecule drug discovery solutions by combining deep biology, chemistry, and machine learning. It creates candidate-ready compounds with high speed and accuracy, using a proprietary big data platform and predictive design models to model protein shapes and design selective compounds that induce precise structural changes for therapeutic effects. The company collaborates with pharmaceutical and biotech firms, licensing its technology and pursuing milestone-based payments, rather than selling products outright. This partnership-centric model helps clients accelerate their drug discovery programs in a highly competitive market. The company aims to shorten the path from target to clinical candidate by delivering well-characterized, selective small molecules efficiently.

Company Size

51-200

Company Stage

Series A

Total Funding

$153M

Headquarters

Boston, Massachusetts

Founded

2023

Get referred to Superluminal Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Lilly's February 2026 update reaffirmed up to $1.3B in payments.
  • Superluminal expects an IND submission in late 2026 for obesity.
  • RA Capital, Insight, NVentures, Catalio, and Lilly funded the $120M Series A.

What critics are saying

  • Lilly gets exclusive rights, so Superluminal loses downstream economics.
  • The lead obesity asset still needs 2026 human data after IND filing.
  • A failed MC4R program would crush platform credibility and future partnering.

What makes Superluminal Medicines unique

  • Superluminal combines protein dynamics, structural biology, and ML on GPCRs.
  • Lilly backed the 2024 Series A and signed a 2025 $1.3B pact.
  • Its lead MC4R obesity program entered IND-enabling studies in July 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Parental Leave

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Training Programs

Tuition Reimbursement

Meal Benefits

Commuter Benefits

Pet Insurance

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

31%

1 year growth

31%

2 year growth

31%
The Pharma Letter
Aug 15th, 2025
Lilly and Superluminal work on GPCR drugs for cardiometabolic diseases

Eli Lilly (NYSE: LLY) has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule therapies for undisclosed G protein-coupled receptor (GPCR) targets linked to cardiometabolic diseases and obesity.

Fierce Biotech
Aug 14th, 2025
Superluminal secures $1.3B pact with backer Lilly to develop cardiometabolic, obesity drugs

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. | Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech.

BioWorld
Aug 14th, 2025
Superluminal, Lilly in $1.3B Deal

Superluminal Medicines Inc. has entered a collaboration with Eli Lilly and Co. in a deal worth up to $1.3 billion. The partnership aims to develop therapies for cardiometabolic diseases and obesity by targeting undisclosed G protein-coupled receptors. The deal includes up-front and near-term investments, an equity investment, development and commercial milestones, and tiered royalties on net sales.

BioWorld
Aug 14th, 2025
Superluminal joins a $1.3B deal with series A backer Lilly

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets.

FinSMEs
Sep 9th, 2024
Superluminal Medicines Closes $120M Series A Funding

Superluminal Medicines, a Boston, MA-based company that uses generative biology, chemistry and machine learning approaches to create medicines, raised $120M in Series A funding